ERBB2 and neoplasm: The use of SUVmax of primary tumour, tumour-to-contralateral, tumour-to-liver, tumour-to-LDM and tumour-to-spleen ratios for the discrimination of HER2-positive and HER2-negative lesions was evaluated using ROC analysis.